Quantitative Phosphoproteomics Analysis Uncovers PAK2- and CDK1-Mediated Malignant Signaling Pathways in Clear Cell Renal Cell Carcinoma.


Journal

Molecular & cellular proteomics : MCP
ISSN: 1535-9484
Titre abrégé: Mol Cell Proteomics
Pays: United States
ID NLM: 101125647

Informations de publication

Date de publication:
11 2022
Historique:
received: 12 09 2021
revised: 23 08 2022
accepted: 19 09 2022
pubmed: 25 9 2022
medline: 29 11 2022
entrez: 24 9 2022
Statut: ppublish

Résumé

Clear cell Renal Cell Carcinoma (ccRCC) is among the 10 most common cancers in both men and women and causes more than 140,000 deaths worldwide every year. In order to elucidate the underlying molecular mechanisms orchestrated by phosphorylation modifications, we performed a comprehensive quantitative phosphoproteomics characterization of ccRCC tumor and normal adjacent tissues. Here, we identified 16,253 phosphopeptides, of which more than 9000 were singly quantified. Our in-depth analysis revealed 600 phosphopeptides to be significantly differentially regulated between tumor and normal tissues. Moreover, our data revealed that significantly up-regulated phosphoproteins are associated with protein synthesis and cytoskeletal re-organization which suggests proliferative and migratory behavior of renal tumors. This is supported by a mesenchymal profile of ccRCC phosphorylation events. Our rigorous characterization of the renal phosphoproteome also suggests that both epidermal growth factor receptor and vascular endothelial growth factor receptor are important mediators of phospho signaling in RCC pathogenesis. Furthermore, we determined the kinases p21-activated kinase 2, cyclin-dependent kinase 1 and c-Jun N-terminal kinase 1 to be master kinases that are responsible for phosphorylation of many substrates associated with cell proliferation, inflammation and migration. Moreover, high expression of p21-activated kinase 2 is associated with worse survival outcome of ccRCC patients. These master kinases are targetable by inhibitory drugs such as fostamatinib, minocycline, tamoxifen and bosutinib which can serve as novel therapeutic agents for ccRCC treatment.

Identifiants

pubmed: 36152754
pii: S1535-9476(22)00225-0
doi: 10.1016/j.mcpro.2022.100417
pmc: PMC9637947
pii:
doi:

Substances chimiques

CDC2 Protein Kinase EC 2.7.11.22
p21-Activated Kinases EC 2.7.11.1
Vascular Endothelial Growth Factor A 0
Phosphopeptides 0
PAK2 protein, human EC 2.7.11.1
CDK1 protein, human EC 2.7.11.22

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

100417

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of Interest The authors declare no competing interests.

Auteurs

Aydanur Senturk (A)

Department of Molecular Biology and Genetics, Koc University, Istanbul, Turkey.

Ayse T Sahin (AT)

Department of Molecular Biology and Genetics, Koc University, Istanbul, Turkey.

Ayse Armutlu (A)

Department of Pathology, Koc University School of Medicine, Istanbul, Turkey.

Murat Can Kiremit (MC)

Department of Urology, Koc University School of Medicine, Istanbul, Turkey.

Omer Acar (O)

Department of Urology, Koc University School of Medicine, Istanbul, Turkey.

Selcuk Erdem (S)

Department of Urology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey.

Sidar Bagbudar (S)

Department of Pathology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey.

Tarik Esen (T)

Department of Urology, Koc University School of Medicine, Istanbul, Turkey.

Nurhan Ozlu (N)

Department of Molecular Biology and Genetics, Koc University, Istanbul, Turkey; Koc University Research Center for Translational Medicine (KUTTAM), Omics Laboratory, Istanbul, Turkey. Electronic address: nozlu@ku.edu.tr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH